Low-cost generation of clinical-grade layperson-friendly pharmacogenetic passports using oligonucleotide arrays

Authors and affiliations

Pauline Lanting[1,2,3*], Robert Warmerdam[1,3*], Jelle Slager[1], Harm Brugge[1], Taichi Ochi[4], Marloes Benjamins[1], Esteban Lopera-Maya[1], Soesma Jankipersadsing[1], Jody Gelderloos-Arends[1], Daphne Teuben[1], Dennis Hendriksen[1,6], Bart Charbon[1,6], Lennart Johansson[1,6], Thijs Oude Munnink[2], Nienke de Boer-Veger[5], Lifelines NEXT, LifeLines Cohort Study, Bob Wilffert[2,4 †], Morris Swertz[1,6], Daan Touw[2], Patrick Deelen[1,3], Nine Knoers[1], Jackie Dekens[1,7#], Lude Franke[1,3#]

[*] Contributed equally

[†] Deceased

[#] To whom correspondence should be addressed

1. Department of Genetics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
2. Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
3. Oncode Institute, Utrecht, The Netherlands
4. Groningen Research Institute of Pharmacy, Unit of PharmacoTherapy, Epidemiology & Economics, University of Groningen, Groningen, The Netherlands
5. Service Apotheek Boterdiep, Groningen, The Netherlands
6. Genomics Coordination Center
7. Center for Development and Innovation, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

Abstract

Pharmacogenomic (PGx) information is essential for precision medicine, enabling drug prescriptions to be personalized according to an individual's genetic background. Almost all individuals will carry a genetic marker that affects their drug response, so the ideal drug prescription for these individuals will differ from the population-level guidelines. Currently, PGx information is often not available at first prescription, reducing its effectiveness. Pharmacogenetic information is most often obtained using special assays, making it expensive and time-consuming to generate. We therefore hypothesized that we could also use genome-wide oligonucleotide genotyping arrays to generate comprehensive PGx information (PGx passports), thereby decreasing the cost and time required for PGx testing, and lowering the barrier to generating PGx information prior to first prescription.

Taking advantage of existing genetic data generated in two biobanks, we developed and validated Asterix, a low-cost clinical-grade PGx passport pipeline for 12 PGx genes. In these biobanks we performed and clinically validated genetic variant calling and statistical phasing and imputation. In addition, we developed and validated a novel *CYP2D6* copy number variant calling tool, foregoing the need to use separate PCR-based copy number detection. Ultimately, we returned 1227 PGx passports to biobank participants via a layperson-friendly app, improving knowledge of PGx among citizens. Our study demonstrates the feasibility of a low-cost clinical-grade PGx passport pipeline that could be readily implemented in clinical settings to enhance personalized healthcare, ensuring that patients receive the most effective and safe drug therapy based on their unique genetic makeup.

Keywords

Pharmacogenetics, pharmacogenomics, PGx profile, PGx passport, clinical pharmacogenomics

1. Introduction

There is now extensive knowledge available on pharmacogenes, and clinical guidelines are available for personalized drug treatment using genetic data (1). However, the application of pharmacogenetics (PGx) in clinical practice remains limited (2) and is mostly done reactively to understand why patients reacted poorly to prescribed drugs. However, a pre-emptive pharmacogenetic passport would allow results to be stored in (electronic) medical files for future medical use (3), ensuring that PGx data are available at first prescription, thereby enabling optimized treatment and preventing adverse effects (4,5). Currently, the major impediments to such pre-emptive testing are cost and speed: PGx information is most commonly obtained using dedicated assays that target a limited subset of haplotypes of a single gene. This makes the generation of a complete, multi-gene profile time-consuming and costly.

In theory, PGx data can also be obtained from genetic data that is routinely used in both research and clinical genetics. Single nucleotide polymorphism (SNP) microarrays in particular have proven essential for detection of Copy Number Variations (CNVs) in clinical genetics and genome-wide association studies (GWAS) in research (6,7). However, whether this data can be used to provide a clinical-grade PGx passport to individuals is largely unknown, and there are a number of challenges that need to be resolved before this data can be effectively used for PGx.

78 Firstly, SNP arrays do not consider every variant and do not capture on which
79 haplotype specific information is located, requiring the use of genotype phasing and
80 imputation. Secondly, *CYP2D6*, an important gene in pharmacogenomics (8) is
81 highly polymorphic, and it is also affected by CNVs, making the genotyping of this
82 gene non-trivial. To deliver on the promise of personalized medicine, we need to
83 bridge these gaps in order to translate available genetic data to clinically relevant
84 PGx data.
85
86 In parallel with the decreasing cost of genetic testing over the past decade, the
87 number of large-scale biobank initiatives has also increased. Jointly, these biobanks
88 have now generated genotype data for millions of individuals (9–12). This provides
89 an opportunity to repurpose readily available genetic data to develop and validate
90 the use of SNP array data for generating PGx passports. This would allow
91 researchers to return clinical-grade PGx results to biobank participants, thereby
92 decreasing the barriers to applying pre-emptive PGx testing and facilitating
93 personalized medicine in clinical settings.
94
95 Another problem is that the disclosure of PGx information so far has mainly been
96 limited to researchers, clinicians, and pharmacists. Yet sharing relevant PGx
97 information with citizens is important to improve knowledge and understanding of
98 PGx testing and its related health outcomes. Digital health technologies, including
99 mobile phone applications, have increased citizen engagement in the last 10 years
100 (13,14), and they allow patients to be engaged in the healthcare decision-making
101 process. Implementation of digital health technology in optimizing medication
102 adherence in patients with depression, respiratory diseases, and cancers has been

103 shown to improve patient outcomes. However, the use of digital health technologies
104 to provide PGx information to patients has been limited. However, with growing
105 populations throughout the world, governments are now actively stimulating the
106 development and use of such tools. For instance, the recent Integral Care
107 Agreement in the Netherlands highlights the importance of digitalization to promote
108 self-reliant digital healthcare (15).
109
110 In the northern Netherlands, the Lifelines Cohort Study, a multigenerational,
111 longitudinal, dynamic cohort and biobank, presents a unique opportunity to leverage
112 available genetic data to facilitate healthy aging (16). This biobank has been
113 genotyping its participants for multiple years, as has the separate Lifelines NEXT
114 prospective birth cohort biobank. In this study, we developed and clinically validated
115 1) an automated software tool for the interpretation of array-based genotype data to
116 generate reliable PGx profiles, 2) a layperson-friendly translation of Dutch
117 Pharmacogenetics Working Group (DPWG) guidelines, and 3) a digital infrastructure
118 to communicate these to biobank participants. By developing this tool, we aim to
119 improve the lives of patients and the general population, starting with the population
120 of the northern Netherlands and expanding to more individuals in the future.
121
122 **2. Methods**
123 *2.1 Datasets and quality control*
124 We used four different datasets to develop and validate the automated generation of
125 PGx passports, divided over two different versions of Illumina Genotyping arrays. We
126 used 38,030 samples from the UMCG Genetics Lifelines Initiative (UGLI) cohort of
127 the Lifelines prospective follow-up biobank (17) to develop and validate an

128 automated PGx passport pipeline using the Infinium Global Screening Array®
129 MultiEthnic Disease (GSA-MD) version 1.0 array. In parallel, we used three datasets
130 to develop the pipeline for the GSA-MD version 3.0 array: 2473 samples from our
131 Genome Diagnostics patient cohort (UMCG), 77 validation samples with known PGx
132 genotypes, and another 574 samples from the Lifelines NEXT cohort (18).
133
134 The samples of the Lifelines UGLI cohort were genotyped using GSA-MD version
135 1.0. We performed quality control on both samples and markers, including removal of
136 samples and variants with a low genotyping call rate (<97%), variants showing
137 deviation from Hardy-Weinberg equilibrium ($p < 1\times10^{-6}$), excess of Mendelian errors
138 in families (>1% of the parent–offspring pairs), and samples with very high or low
139 heterozygosity (4 standard deviations (SD) above or below the mean for autosomes).
140 We further revised and removed samples that did not show consistent information
141 between reported sex and genotypes on the X chromosome, or between reported
142 familial information and observed identity-by-descent sharing with family members.
143 All other samples were genotyped using GSA-MD version 3.0 and were quality-
144 controlled similarly to those in Lifelines UGLI. In total, 36,373 Lifelines UGLI
145 samples, 470 Lifelines NEXT samples, 2285 validation samples of the Genome
146 Diagnostics patient cohort, and 76 validation samples with known PGx genotypes
147 passed quality control.
148
149 *2.2 Selecting individuals to receive pharmacogenetic results*
150 Quality control measures in research settings are commonly less stringent than in
151 diagnostics. Since Lifelines UGLI samples were genotyped in a research setting, this
152 dataset could potentially contain sample swaps. Therefore, we used the Idéfix (19)

153 select a high-quality subset of 5,765 samples suitable for returning personalized
154 results. In short, Idéfix selects those samples for which the actual phenotypes
155 sufficiently match the predicted phenotypes based on genetic predispositions. These
156 genetic predispositions were determined by calculating polygenic scores (PGSs) per
157 phenotype. These calculations aggregate the effects of common risk-decreasing or -
158 increasing alleles identified by GWAS. Here, we reran Idéfix using an updated list of
159 PGSs based on recent GWAS. Quality control, PGS calculation, and running Idéfix
160 were performed as described in Warmerdam et al. (19). Finally, we returned PGx
161 results to 996 active Lifelines participants who gave consent to receive their PGx
162 passport. For Lifelines NEXT, we were able to manually resolve sample swaps
163 based on family data and duplicated array runs. We returned PGx results to 231
164 mothers registered as active Lifelines NEXT participants who gave consent to
165 receive their PGx passport.
166
167 *2.3 Variant calling*
168 Variants were called in two separate stages. In general, we used the Opticall
169 software (20) to do genotype-calling on the majority of variants. However, Opticall is
170 not suitable for genotyping variants covering frequent CNVs. Since CYP2D6 is
171 affected by relatively frequent CNVs, it is not trivial to genotype variants within and
172 near this gene. At the same time, inclusion of CYP2D6 is essential to return a
173 comprehensive PGx passport because it metabolizes a large proportion of
174 medication. We therefore developed a novel algorithm for CNV-calling of the
175 CYP2D6 gene using the data obtained from a SNP array. In addition, this method
176 also performs genotype-calling of individual variants in the CYP2D6 gene.
177

178 *2.3.1 CYP2D6*

179 SNP arrays have been used extensively to study both SNPs and CNVs. Modern
180 SNP arrays genotype at hundreds of thousands of assays (probes designed to
181 genotype one particular variant) simultaneously by measuring the color and intensity
182 of light emitted when one of four labeled nucleotides hybridizes at the assays. In
183 addition to enabling study of which alleles are present in an individual through
184 comparison of the colors of the emitted light, it also allows study of CNVs by
185 combining the total signal intensity. We combined these two approaches in our
186 *CYP2D6* genotyping methodology, as described below.

187

188 For genotyping *CYP2D6*, we first selected a number of independent, high-quality
189 variants from the quality-controlled genetic data (missingness < 0.01, minor allele
190 frequency (MAF) > 0.05, Hardy-Weinberg equilibrium p-value > 0.05, *HLA* excluded,
191 minimum distance of 100kb between variants, $R^2 < 0.4$). Using these variants, our
192 method performs a principal component analysis of the intensities of the selected
193 variants (summed across the two alleles). As the first principal components (PCs)
194 likely tag batch effects, we chose to regress out the first 100 PCs from the genomic
195 region of interest – the *CYP2D6* gene – using ordinary linear regression (OLS). Both
196 PC loadings and OLS regression parameters can be estimated in one dataset, and
197 later applied in another. The methodology for correcting SNP array intensities follows
198 the approach previously established by Lude Franke et al. (21).

199

200 After correction for batch effects, one variant is selected to assign naive CNV-calls
201 (rs1135824 for GSA-MDv1, rs1423323203 for GSA-MDv3). Naive, preliminary CNV
202 assignments are made by binning the total signal intensity of the selected variant so

203 that the proportions of CNV genotypes match the expected frequency of CNV-calls.
204 The expected frequencies (*5 = 0.0295, Duplication = 0.0275) are obtained from
205 PharmGKB (https://www.pharmgkb.org/page/cyp2d6RefMaterials, European
206 population). Using the means and SDs of the signal intensities for each bin, a naive,
207 preliminary CNV call is assigned to every individual based on which CNV bin has the
208 highest likelihood at the signal intensity of the specific variant. If multiple GSA probes
209 are available for a variant, a majority voting ensemble classifier is used to obtain a
210 consensus of the various assays. Next, genotyping is performed using a manually
211 selected set of variants. These variants are selected based on whether the individual
212 signal intensities show clusters of genotypes in accordance with what can be
213 expected for a biallelic variant with possible deletions and duplications (i.e., at least
214 six visible intensity clusters rather than the three intensity clusters expected when
215 dealing with a biallelic variant outside a CNV).
216
217 For each variant and possible copy number, a nearest-neighbors classifier is used to
218 obtain a set of highly confident samples for every variant. Then, to perform
219 genotyping, the theta of every sample is calculated based on its intensities. For this,
220 the median of the intensities for the samples naively assigned to the group of
221 homozygous deletions is used as the origin. Thereafter, samples are binned into k
222 bins, where k corresponds to the number of genotypes that can be expected for a
223 biallelic variant at each copy number. Bins are assigned genotypes so that they best
224 match Hardy-Weinberg principles. Per variant, naive genotype clusters are then
225 iteratively improved in a gaussian mixture model algorithm adapted from *scikit-learn*
226 (22). The maximization step in the gaussian mixture model algorithm was changed to
227 also weight genotypes according to Hardy-Weinberg principles, which were

228 expanded to also take deletions and duplications into account. Per variant, this
229 procedure is performed while accounting for the intensity measures of all assays
230 tagging that specific variant.
231
232 For each combination of a variant, sample and copy number, a total probability is
233 calculated by summing the probabilities across the genotypes corresponding to that
234 copy number. Subsequently, the most likely copy number is assigned to each
235 variant-sample combination by selecting the copy number with the largest total
236 probability among the possible copy numbers. The CNV status of *CYP2D6* as a
237 whole is determined by summing the probabilities of variants over all possible copy
238 numbers, and rescaling these to sum to one. Genotype probabilities are then
239 calculated by rescaling the possible genotype probabilities in the assigned copy
240 number status to one.
241
242 Genotypes of samples with 1 or 2 *CYP2D6* copies (across both the maternal and
243 paternal chromosome) are written so that genotypes of samples with single-gene
244 deletions are homozygous for the reanalyzed variants. Genotypes for variants of
245 samples that are homozygous for whole-gene deletions do not exist. In human
246 genetic datasets, the representation of genotypes for variants of samples with a
247 *CYP2D6* duplication is not trivial, making the imputation and phasing non-trivial.
248 Therefore, these samples are excluded. *CYP2D6* variants in chromosome 22
249 genotyped using Opticall are replaced with the newly genotyped *CYP2D6* variants.
250 This is subsequently used in the phasing and imputation pipeline. The *CYP2D6*
251 CNV-calling algorithm is included as the first part of the *Asterix* software that we
252 developed to generate PGx profiles.

253 *2.4 Phasing and imputation pipeline*

254 Before phasing and imputation, PLINK files are lifted from Human genome build 37
255 to build 38 and alleles of insertions and deletions are recoded to match the notation
256 in the reference dataset. Then, variants for which the strands do not match the
257 reference panel are removed, and variants with >5% missingness or a Hardy-
258 Weinberg p-value < $1x10^{-6}$ are removed. Phasing and imputation are implemented
259 using Eagle v2.4.1 (23) and Minimac4 (24)(version 1.0.2). The reference dataset for
260 phasing and imputation is derived from the 1000 Genomes project 30x coverage
261 whole genome sequencing dataset (25). Finally, we replaced the imputed genotypes
262 with the original genotypes for the variants that were used as input in the imputation.

263

264 *2.5 Crucial backbone*

265 A minimum set of variants that should be included in our genotyping panel was
266 determined per gene (see Table S1). We used available 'tier 1' recommendations for
267 *CYP2C9*, *CYP2C19*, *CYP2D6, CYP3A4, CYP3A5,* and *VKORC1* (26–29). For the
268 other genes in our PGx passport, we assessed the variants/alleles that were
269 mentioned in DPWG background information and those that are included in our
270 validation dataset. We included a variant in the crucial backbone when: 1) the variant
271 results in an allele known to alter the drug response phenotype, and 2) the MAF in
272 the (North-Western) European population is > 0.001.

273

274 *2.6 Validation*

275 We validated GSA-MD versions 1 and 3 and *Asterix* following the clinical genome
276 diagnostic standards in our center. The validation parameters and corresponding
277 acceptance criteria are shown in Table 1.

278 *Table 1: Validation parameters and acceptance criteria for the clinical validation of the Infinium Global Screening*
279 *Array MultiEthnic Disease versions 1 and 3, and the software tool* Asterix. *‡For all variants available in both*
280 *gnomAD-NFE and GoNL datasets, the distribution of mutant allele frequency differences between those two*
281 *datasets was recorded. Z represents the standard deviation of that distribution. Variants that deviated more than*
282 *3*Z from the gnomAD-NFE mutant allele frequency failed validation.*

Topic	Validation parameter	Acceptance criterium
Quality of the array data	Call rate	³0.97
Phasing and imputation quality	Concordance with trio-data	³0.97
	R^2	³0.97
Result interpretation	Absolute number of mutant alleles detected	³5
	Mutant allele frequency	<3*Z‡
	Concordance with known genotypes	100%

283

284 We created a benchmark set of haplotypes using data of 621 (GSA-MD v1) and 135
285 (GSA-MD v3) parent–offspring trios to validate phasing performance. Using
286 *SHAPEIT5* (30) we then compared the results of our statistical phasing with the
287 benchmark haplotypes and computed the switch error rates (SER) of all genetic
288 variants that were directly typed. The call rate and imputation quality are validated
289 based on the output of our quality control procedures. Variants were removed if: 1)
290 they were not directly genotyped nor imputed, 2) they were not in the crucial
291 backbone and had a low imputation probability ($R^2 < 0.97$), 3) the mutant allele was
292 observed < 5 times in the full dataset, 4) the mutant allele frequency deviated more
293 than 3*Z from the gnomAD-non-Finnish Europeans (NFE) mutant allele frequency (Z
294 represents the SD of differences in mutant allele frequency between the GoNL and
295 gnomAD-NFE datasets), 5) the phasing SER was > 0%, or 6) the concordance with
296 known genotypes of validation samples was < 100%.

297

298 When a variant was in the crucial backbone, but the imputation probability was low,
299 we used haploid-level dosage (HDS) to assess the variant call confidence level in an
300 individual sample.
301
302 In addition to variant calling, we also validated our CNV-calling algorithm. To that
303 end, we selected samples with a confidence score of > 0.97 (1x zero copies, 14x one
304 copy, and 16x two copies) and samples with a confidence score of with a CNV-
305 calling confidence score of > 0.9, and < 0.97 (4x one copy, 3x two copies and 5x
306 three copies). DNA of these samples was analyzed with a dedicated TaqMan real-
307 time PCR assay specifically targeting exon 9 of the *CYP2D6* gene (Certe,
308 Groningen, the Netherlands). It is worth noting that this assay cannot detect gene
309 duplication or hybrid alleles. However, as we report *CYP2D6* to be not available
310 when >2 copies of *CYP2D6* are detected, these calls do not currently require
311 validation.
312
313 Finally, we confirmed that the software we developed correctly translated 1) the
314 detected mutations to the corresponding star alleles and, subsequently, 2) the
315 combination of haplotypes to the corresponding contraindication (CI) and/or
316 predicted phenotype. This is described in more detail in section 2.9.3 and in the
317 Supplementary Information.
318
319 *2.7 Pruning of allele definition tables*
320 We used gene-specific allele definition tables to assign star alleles. Available tables
321 were downloaded from PharmVar (v5.2.14 for GSA-MD version 3; v6.0.5 for GSA-
322 MD version 1) for *CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5* and

323 *NUDT15* and from PharmGKB for *ABCG2* and *TPMT*
324 (https://www.pharmgkb.org/page/pgxGeneRef). Custom tables were constructed for
325 *MTHFR, SLCO1B1* and *VKORC1*. We curated all allele definition tables for the GSA-
326 MD versions 1 and 3 separately and removed all variants that did not pass
327 acceptance criteria (Tables S2a-b). We then pruned each table to prevent
328 ambiguous calls caused by haplotypes that we cannot distinguish based on the
329 variants included in our pipeline. The resulting allele definition tables are shown in
330 Tables S3a-x.
331
332 *2.8 Translation to pharmacogenetic contraindication*
333 To translate the diplotype to the PGx CI used in medication surveillance, we
334 designed custom translation tables (see Tables S4a-l). Allele function of individual
335 star alleles and their translation into predicted phenotype and PGx CI are based on
336 PharmVar, PharmGKB, and/or DPWG background information. All possible
337 diplotypes based on the pruned allele definition tables are included in the translation
338 tables. We made sure the PGx CIs correspond to those used in the DPWG
339 recommendations.
340
341 *2.9 Generating PGx profiles*
342 We developed the *Asterix* tool to produce PGx profiles from genotyping data from
343 the GSA-MD versions 1 and 3. *Asterix* is composed of four main tasks: 1)
344 determining the *CYP2D6* copy number status, 2) determining star alleles, 3)
345 translating these to predicted phenotypes and PGx CIs, and 4) constructing a
346 logging file.
347

348 *2.9.1 Determining star alleles, predicted phenotypes, and PGx CIs*

349 After correction of the *CYP2D6* genotypes based on the CNV status, star alleles for
350 all included genes are assigned using the gene-specific allele definition tables.
351 Subsequently, predicted phenotypes and PGx CIs are determined with the custom
352 translation tables. When determining star alleles present for *CYP2D6*, *Asterix* takes
353 into account whether whole-gene deletions (*CYP2D6*5*) were detected in CNV-
354 calling.

355

356 *2.9.2 Constructing a logging file*

357 To be able to check *Asterix* output, an extensive logging file is constructed that
358 contains information for several checkpoints in our pipeline. Parameters that are
359 logged include the estimated phased haploid-level dosage (HDS) when < 0.97 (only
360 for imputed genotypes), missing variants, and haplotypes that were not described in
361 translation tables. Identical haplotypes are merged together to simplify the validation
362 process.

363

364 *2.9.3 Approval and release of the PGx profiles*

365 The PGx profiles generated are to be released by a registered pharmacist. To
366 maximize process efficiency, the approval and release of the PGx profiles is
367 performed on the level of unique combinations of detected mutations and unreliable
368 calls. When a sample contains only previously approved haplotypes, it is
369 automatically released. Each decision is logged to maintain an audit trail. The
370 procedure for approving and releasing the profiles is described in more detail in the
371 Supplementary Information.

372

373 *2.10 Building layperson-friendly PGx passports*

374 The output of *Asterix* is a PGx profile that is suitable for application in clinical practice
375 by healthcare practitioners. However, (future) patients should not be expected to
376 understand the meaning or implications of such a profile. We therefore developed a
377 layperson-friendly digital PGx passport to fulfill the informational needs of (future)
378 patients.

379

380 *2.10.1 Developing layperson-friendly communication materials*

381 We aimed to develop communication materials that explain the impact of drug–gene
382 interactions (DGIs) that are understandable for 90% of the study population. We
383 developed layperson-friendly texts based on the DPWG guidelines for healthcare
384 practitioners (see Table S5), written at Common European Framework of Reference
385 Common Reference Level B2 (31). One important difference that we had to address
386 is that the DPWG guidelines do not contain an explanation for normal metabolizers
387 because standard-of-care applies for these patients. However, texts for the (future)
388 patient do need to cover this topic because it is valuable to explain that standard-of-
389 care applies. The texts are constructed using three building blocks (Figure 1).

390

Block 1: Predicted influence of your DNA. The *generic drug name* is used and the nature of the DGI is explained. The PGx result, including possible implications such as increased or decreased chance of ADRs and/or efficacy and recommendations for drug use is explained. A reference to the physician or pharmacist for more information is included for actionable DGIs.	**Predicted influence of your DNA** How well amitriptyline is processed by the body varies from person to person. This is, in part, determined by your DNA. Your genes show that *amitriptyline* is processed much more slowly than average by your body. The normal dosage can, therefore, lead to a higher chance of side effects. You will probably need a lower dose of *amitriptyline*. Your physician or pharmacist can tell you more about the appropriate dose.
Block 2: Advice. Statement when sharing the PGx result with the physician or pharmacist would be wise. An explanation that a dose currently in use may already be tailored sufficiently is included, as well as a reminder to never change drug use	**Advice** If you are using or, in the future, get prescribed *amitriptyline*, it would be wise to share the information in your Pharmacogenetic Passport with your physician or pharmacist, so they can take this into account. Your physician and pharmacist also consider factors such as age, sex, and other medication you might be using. Based on that

Figure 1: Building blocks used to construct layperson-friendly texts to explain Drug–Gene interactions (left) and the corresponding text for CYP2D6 PM-amitriptyline (translated from Dutch, right).

2.10.2 Digital infrastructure

We created a DGI table that contains all the CIs produced by *Asterix*, a list of known DGIs currently in the DPWG guidelines, and the layperson-friendly texts associated

398 to each combination of these. The relevant texts for each participant are selected
399 based on their PGx profile and known DGIs. For example, the text explaining the
400 consequences for amitriptyline in Figure 1 will be selected for the individuals who are
401 listed as CYP2D6 PM in their PGx profile. The PGx profile and corresponding texts
402 are subsequently unlocked through an Application Programming Interface (API)
403 following the Health Level Seven Fast Healthcare Interoperability Resources (HL7-
404 FHIR) format. Participants can view their PGx passport in the mobile application
405 (app) *Gen en Geneesmiddel,* which we developed with Synappz Digital Healthcare
406 and which is available for iOS and Android (see Figure 4).
407
408 *2.10.3 Additional features*
409 Upon installing the app, the user is shown a series of information screens that
410 explain PGx and the content and use of the app. This information can be reviewed
411 within the app after completion of this initial onboarding process. Furthermore,
412 frequently asked questions (FAQ) are included in the app to address several
413 anticipated questions. The FAQ-section is supplemented by new questions from
414 users and associated answers.
415
416 The layperson-friendly texts displayed in the mobile application are accompanied by
417 articles that describe the PGx CI that interacts with the drug being viewed (see Table
418 S5). When multiple PGx CIs are relevant for the drug being viewed, all the relevant
419 articles are shown. The articles provide interested participants with more detailed
420 information and facilitate communication between (future) patients and healthcare
421 practitioners.
422

423 Finally, a technical report aimed at healthcare practitioners can be downloaded from
424 the app. This report contains the PGx profile and accompanying information,
425 including contact information for a helpdesk and instructions on how to interpret and
426 process the results.
427
428 **3. Results**
429 *3.1. Pharmacogenomic profiles and passports*
430 To validate the use of a layperson-friendly, clinical-grade PGx passport using
431 oligonucleotide arrays, we have developed a tool (*Asterix*) to produce PGx profiles
432 from genotyping data from the GSA-MD versions 1 and 3. As described in Figure 2a,
433 our tool works by determining the *CYP2D6* copy number, phasing and imputing
434 genetic variants, determining the star alleles of the samples provided, and translating
435 diplotypes to PGx CIs. Instructions on the installation and use of *Asterix* are
436 described on the GitHub repository (https://github.com/molgenis/asterix).
437
438 *3.2. Validation*
439 A total of 34 variants, in 12 genes, were included in the crucial backbone of the PGx
440 pipeline, and subsequently underwent validation (Table 2). For *CYP2B6* we initially
441 also included rs3211371 (**5*). However, since the DPWG withdrew CI definitions
442 differentiating *CYP2B6*5* from **1*, we removed this SNP from the crucial backbone.
443 Three variants in *CYP2C9* (rs28371686 (**5*), rs9332131 (**6*) and rs7900194 (**8*))
444 were initially included in the crucial backbone based on their multiethnic allele
445 frequency (26). However, since each of these variants had a MAF < 0.001 in the
446 NFE population, we subsequently excluded them from the crucial backbone for GSA-
447 MD v1. It is important to note that the Lifelines population is known to be reflective of



Figure 2: Overview of the work in this paper. (a) Schematic of the pharmacogenetic (PGx) pipeline developed to generate PGx profiles. Data collection involves obtaining DNA samples from participants and genotyping using an oligonucleotide array. We ascertain CYP2D6 *copy numbers (CN) using a custom CNV calling approach. This method estimates CN status at multiple points within the* CYP2D6 *gene and integrates these estimates to determine the overall gene copy number status. Twelve genes contribute to the generation of PGx profiles. The combined effects of these genes are aggregated into medication-level recommendations, which are communicated to participants via a layperson-friendly app. (b) Broad overview of the methodology used for validating the PGx pipeline. (c) Overview of the datasets used for development and validation of the PGx passport (Development datasets), and those for which we also returned PGx-profiles (Repurposed datasets).*

459 the NFE population. For the same reason, we excluded rs41303343 (*CYP3A5*7*).
460 For *TPMT* variant rs1800462 (**3A*/**3B*), no mutant alleles were detected on GSA-MD
461 v3. As we could not ensure the associated GSA probe was functional, *TPMT* was
462 excluded from PGx profiles generated with GSA-MD v3. All other variants in the
463 crucial backbone passed validation criteria. In case of an imputation score (R^2) <
464 0.97, imputation quality was judged from sample-specific HDS. When the HDS <
465 0.97, a registered pharmacist decided during approval and release whether a result
466 could be released for the associated gene.
467

468 *Table 2: Validation results of crucial backbone variants.*
469 *[a]rs28371686, rs9332131, and rs7900194 were left out of crucial backbone for GSA-MD v1, based on known*
470 *ethnic composition of Lifelines*
471 *[b]rs41303343 was left out of the crucial backbone for both GSA-MD v1 and GSA-MD v3, based on known ethnic*
472 *composition of Lifelines*
473 *[c]Reference allele frequency in non-Finnish Europeans (NFE)*

			GSA-MD v1		GSA-MD v3		
Gene	**rsID**	**Alt. allele frequency[c]**	**method**	**R^2**	**method**	**R^2**	**failed validation**
ABCG2	rs2231142	0.1092	direct		direct		
CYP2B6	rs3745274	0.2372	direct		direct		
CYP2C19	rs4244285	0.1480	direct		imputation	0.99	
	rs4986893	0.0002	direct		direct		
	rs12248560	0.2200	direct		direct		
CYP2C9	rs1799853	0.1266	imputation	0.99	imputation	1.00	
	rs1057910	0.0662	direct		direct		
	rs28371686	0.0000	(*imputation*)[a]	(*0.02*)	direct		
	rs9332131	0.0001	(*imputation*)[a]	(*0.00*)	direct		
	rs7900194	0.0005	(*imputation*)[a]	(*0.01*)	imputation	0.90	
	rs28371685	0.0029	direct		direct		
CYP2D6	rs1135840	0.5588	imputation	0.87	imputation	0.93	
	rs16947	0.3347	imputation	0.89	imputation	0.96	
	rs35742686	0.0170	imputation	0.79	imputation	0.82	
	rs3892097	0.1986	imputation	0.91	imputation	0.92	

	rs5030655	0.0117	imputation	0.61	imputation	0.27	
	rs5030656	0.0285	imputation	0.67	imputation	0.70	
	rs1065852	0.2225	imputation	0.91	imputation	0.95	
	rs28371706	0.0011	direct		imputation	0.86	
	rs61736512	0.0006	imputation	0.04	imputation	0.97	
	rs59421388	0.0006	imputation	0.04	imputation	0.97	
	rs1058164	0.5525	imputation	0.86	imputation	0.93	
	rs28371725	0.0955	imputation	0.84	direct		
CYP3A4	rs35599367	0.0492	direct		direct		
CYP3A5	rs776746	0.9311	direct		direct		
	rs10264272	0.0009	direct		direct		
	rs41303343	0.0004	(*imputation*)[b]	*(0.96)*	*n/a*[b]		
MTHFR	rs1801133	0.3373	direct		direct		
NUDT15	rs116855232	0.0029	direct		direct		
SLCO1B1	rs4149056	0.1587	direct		direct		
TPMT	rs1800462	0.0024	imputation	0.46	direct		<5 mutants detected
	rs1800460	0.0382	imputation	0.96	direct		
	rs1142345	0.0423	imputation	1.00	direct		
VKORC1	rs9923231	0.3779	direct		direct		

We considered 731 and 703 variants outside the crucial backbone for inclusion in the translation tables of GSA-MD v1 (PharmVar tables v6.0.5) and GSA-MD v3 (PharmVar tables v5.2.14), respectively. Results of the validation process are summarized in Figure 3 and are fully available in Tables S2a-b. Many variants were removed due to unavailability on the genotyping arrays and in the imputation panel. Beyond that, poor imputation score and/or low allele frequency were the leading reasons for exclusion. Phasing quality was verified by comparison to phasing results using parent–offspring trios. Poorly phased variants were retained when they were the only variant of interest in that gene, rendering phasing irrelevant. Importantly, 37 variants were typed in 76 validation samples, using a traditional DNA amplification genotyping method (Leiden University Medical Center). For all 37 variants, the

486 genotypes derived from GSA-MD v3 (19 directly typed, 18 imputed) were a 100%

487 match to the traditional assays.

488



489

490 *Figure 3: Validation status of variants from the PharmVar translation tables outside the crucial backbone. The*

491 *UpSet plot displays the frequency of variants that either meet or fail to meet the validation criteria. Columns with*

492 *a single marked circle represent the frequency of variants failing exclusively that criterion, while columns with*

493 *multiple marked circles indicate variants that failed multiple corresponding criteria.*

494 Within *Asterix*, we embedded a custom CYP2D6 copy number (CN) calling

495 algorithm. To validate the *Asterix*-derived *CYP2D6* CN calls, a total of 43 samples

496 were selected, representing a CN probability of at least 0.9 and each of the four

497 possible CN calls (zero copies, one copy, two copies, and three copies). The CN

498 status of the aforementioned samples was determined using a dedicated TaqMan

499 assay targeting exon 9. To compare the results, we initially evaluated whether the

500 overall CN calls with a moderate probability of over 0.9 matched the calls reported by

501 the TaqMan assay (Figure 4a). Of the 43 samples, *Asterix* identified three as having

502 a CYP2D6 duplication (three copies), whereas the TaqMan assay reported these

503 samples as homozygous reference (two copies). In one instance, *Asterix* reported a

504 heterozygous deletion (one copy) while the TaqMan assay returned a homozygous

505 reference call. However, for these four samples, *Asterix* consistently reports a
506 homozygous reference call at exon 9, which is consistent with the call reported by
507 the TaqMan assay. For the majority of the other variants, *Asterix* reports calls
508 matching that of the overall aggregated estimate (Figure 4b). This suggests that
509 these samples are likely to possess a hybrid allele or tandem arrangement, resulting
510 in a distinct CN call at exon 9. It is worth noting that the TaqMan assay is not
511 capable of differentiating between regular copy numbers and hybrid alleles. At a
512 probability of at least 0.97, all 31 samples exhibit matching CN calls.
513
514 Based on the validated variants, final translation tables were created to first translate
515 variants to haplotypes (Tables S3a-x) and then to translate diplotypes to CI (Tables
516 S4a-l). These tables were then used as input for *Asterix* to create preliminary PGx
517 profiles for 996 Lifelines participants and 470 Lifelines NEXT participants. Approval
518 (or adjustment) and release by a registered pharmacist resulted in the final PGx
519 profiles. Haplotype frequencies were compared to reference frequencies in a
520 European population (source: Clinical Pharmacogenetics Implementation
521 Consortium (CPIC)) or NFE (source: DPWG/gnomAD) (Figure 5 and Tables S6a-b).
522
523 Finally, the technical PGx profiles were shared with the biobank participants in the
524 smartphone application *Gen en Geneesmiddel* (Figure 4). The app links the
525 technical information in the PGx profile with associated explanatory texts, yielding a
526 layperson-friendly PGx passport. Rather than using genes as the basic unit of
527 information, the app categorizes drugs into five categories (Figure 4A): poor
528 metabolism (‘very slow’), intermediate metabolism (‘slow’), normal metabolism
529 (‘average’), ultrarapid metabolism (‘very fast’), and non-metabolic drug–gene

interactions (‘other processes’). By selecting one of the categories, users can see a list of all the medications in that category, based on their pharmacogenetic profile (Figure 4B). More information can be found on specific medication (Figure 4C), i.e., what is it used for and how is it affected by the user’s PGx profile. Interested users can get more information on the associated CIs by proceeding to a linked article. Finally, the technical information (PGx profile) can be downloaded and/or shared directly from the app (Figure 4D).

Based on the PGx profiles we generated using *Asterix*, 92% and 90% of the Lifelines and Lifelines NEXT populations, respectively, carried at least one actionable PGx CI (Tables S6a-b list frequencies of PGx haplotypes and CIs). We have returned these profiles to the biobank participants through the *Gen en Geneesmiddel* app, enabling them to get optimized (future) drug prescriptions with the help of their physician and pharmacist.



Figure 4: Overview of the ‘Gen en Geneesmiddel’ app. a) Main menu, where five categories can be selected: ‘poor’, ‘intermediate’, ‘normal’ and ‘ultrarapid’ metabolism and ’other processes’. b) A personalized list of medication in the ‘ultrarapid metabolism’ category. c) Explanation of the predicted metabolism of codeine. d) The pharmacogenetic profile can be saved or shared from the app.



Figure 5: Validation results of CYP2D6 CNV-calling (a, b). a) correspondence between a standard CYP2D6 CNV-calling procedure using a TaqMan assay (x-axis) and the CNV-calling results determined using GSA-MD v3 and our specially designed algorithm. Only exon 9 was assessed in the TaqMan assay. The y-axis for the three graphs shows the copy number (CN) status determined from the array for a variant at exon 9 only (left), for the overall CN status at a probability threshold of 0.90 (middle), and for the overall CN status at a probability threshold of 0.97 (right). b) the CN status for the four deviating samples with a probability threshold of 0.90 over all variants included in the CNV-calling algorithm. c) Haplotype frequency differences compared to the frequencies reported by CPIC (left) and contraindication frequency differences compared to the frequencies reported by CPIC (right).

561 **4. Discussion**

562 In this study, we use oligonucleotide genotyping arrays to develop a low-cost PGx
563 passport that repurposes existing genotype data from the Lifelines and Lifelines
564 NEXT cohorts for clinical use. We clinically validated the genotyping method by
565 aligning validation parameters and corresponding acceptance criteria to the local
566 clinical diagnostic center and by comparing genotyping results with results from
567 classical PCR-based assays. Using parent–offspring trios, we could also verify the
568 accuracy of haplotype phasing, information that is unavailable when using PCR-
569 based PGx assays. We showed that we could confidently include most of the
570 recommended 'tier 1' PGx variants for the genes included in our study (26–29), with
571 only a few exceptions. *TPMT* was excluded for the GSA-MDv3 oligonucleotide array
572 because variant rs1800462 did not meet validation criteria. In addition, three
573 *CYP2C9* variants classified as tier 1 (mutant allele frequency > 0.001) were excluded
574 from the crucial backbone on the grounds of their much lower allele frequencies in
575 the European population. To apply our pipeline in a broader context, these variants
576 would need to be validated in a population with higher MAFs.

577

578 Furthermore, to address previously identified barriers to use of PGx passports by
579 laypeople, we implemented communication of relevant PGx information through a
580 newly developed smartphone application. As the uptake of the PGx passport
581 increases, support will be provided for healthcare professionals to properly apply
582 PGx in their daily practice.

583

584 *4.1 Producing PGx profiles*

585 As the generation of clinically valid PGx profiles from array-based genotype data is
586 the cornerstone of this study, we discuss this first. We did not include *DPYD, FV,*
587 *HLA-A, HLA-B, CYP1A2,* and *COMT* in the PGx passport because: 1) *DPYD*
588 genotyping is already pre-emptively performed in combination with phenotyping in
589 routine care, 2) the DPWG guidelines for mutations in *FV* were retracted, 3) there is
590 no allele definition table for determining *HLA* alleles, so we could not use the same
591 pipeline for this region, and 4) *CYP1A2* and *COMT* are part of DPWG guidelines but
592 currently do not contain DGIs.

593

594 An important limitation in our passport production is that we could not provide a
595 complete passport for every individual. We used imputation quality (R^2) to select
596 imputed variants of sufficient quality. If a variant with insufficient imputation quality
597 ($R^2 < 0.97$) was in the crucial backbone, the variant was not removed from the
598 translation tables, as that would lead to the complete exclusion of the corresponding
599 gene for all individuals. Instead, we use haploid dosage scores to select a subset of
600 individuals with imputed genotypes of sufficient quality. We could thereby still report
601 results for a subset of individuals. When applying our method in a diagnostic setting,
602 genotypes should be determined by a back-up analysis if no reliable result can be
603 extracted from the array data.

604

605 We confirm that actionable PGx variants are present in >90% of the general
606 population, comparable to the percentages reported in literature. In this
607 implementation study, we were unable to evaluate the impact of these actionable
608 variants on drug efficacy and adverse effects, due to the scale of our study and the

absence of high-quality prescription records for our study populations. In the future, we aim to further investigate this by linking prescription data from an external database through the Pharmlines initiative (28).

4.2 Layperson-friendly communication of PGx passports

Engaging patients with PGx testing is not limited to increasing their understanding of genetic information, it is also meant to enable their participation in prescription decisions. Patients who are well-informed about the implications for their prescription management are better equipped to collaborate with their healthcare providers in developing personalized treatment plans that align with their needs and preferences (32). Furthermore, this engagement builds a sense of empowerment and ownership over one's health, which has been shown to improve adherence to treatment regimens and to lead to better health outcomes (33).

The PGx passport, as a digital health tool, facilitates patient engagement by providing a platform to exchange PGx information and medication management to enhance patient understanding. By providing layperson-friendly communication within the PGx passport, it may in the future be used to support patient education initiatives to broaden the understanding and implementation of pharmacogenomics across the Netherlands.

We aimed to develop communication materials that are understandable for 80% of the general population. Since the Lifelines and Lifelines NEXT cohorts are more highly educated than the general population, we speculate that the material should be understandable for around 90% of the study population. In an ongoing

634 implementation study, we will evaluate the level of comprehension among
635 participants, so that texts can be better adapted to citizens' needs.
636
637 Several practical decisions were made in the development of the smartphone
638 application. For example, *CYP3A5* non-expressers (*3/*3) were placed in the app
639 category that represents normal metabolism, while both hetero- and homozygous
640 expressers are placed in the ultrarapid metabolism category. In the Netherlands,
641 *CYP3A5* non-expressers are most prevalent, so the standard of care applies for
642 people with this metabolizer status.
643
644 *4.3 Future perspectives*
645 The completion of the PGx passport and smartphone application represents another
646 step forward on the road toward true personalized medicine. By demonstrating to
647 healthcare professionals how incorporating PGx into daily practice works to
648 streamline prescribing practices through the added value of reduced adverse effects,
649 the PGx passport aims to lower the barrier to making key prescription decisions.
650
651 Although clinical implementation of PGx has picked up pace in the past years, it has
652 not yet been integrated into routine care. One of the main barriers here is likely to be
653 the lack of strong evidence that its application effectively improves healthcare and
654 reduces healthcare costs, which are both prerequisites for reimbursement (34).
655 Other important potential barriers are the complexities associated with integrating
656 genetic data into electronic health records and the need to ensure that healthcare
657 professionals have the requisite expertise and resources to comprehend and utilize

658 PGx insights (35,36). Previous research at our center has shown that, although
659 these barriers exist, they can be overcome (2).
660
661 In this study, we have demonstrated that PGx passports can be generated much
662 more cheaply than the currently prevailing methodologies. However, the efficacy and
663 cost-effectiveness of pre-emptive PGx testing still needs to be more thoroughly
664 proven, and this will require the inclusion of large numbers of participants from the
665 general population. Only then will the numbers of drug prescriptions dispensed
666 based on the information in a PGx passport be sufficient to perform quantitative
667 analysis of adverse effects and/or treatment effectiveness. As the PGx passport is
668 currently limited to the Netherlands, the findings on cost-effectiveness would only be
669 applicable to the Netherlands. However, with the push to harmonize the European
670 Health Data Space, demonstrating cost-effectiveness in the Netherlands will enrich
671 the changing digital health space. Lastly, as the initial data was derived from the
672 Lifelines biobank, incorporating *Asterix* into future investigations in Lifelines would
673 enable more in-depth research into the interplay between genetic variation,
674 environment, population health, and pharmacotherapy.
675
676 *4.4 Concluding remarks*
677 This study provides a method to produce low-cost, clinically validated PGx profiles
678 for use by healthcare professionals from genotype array data. As more and more
679 individuals are genotyped, both in academic and healthcare settings, translating
680 available genetic data towards clinical decision-making will be essential for
681 personalized care. Furthermore, we have developed a smartphone application to
682 ensure that the results from our pipeline, *Asterix,* reach those whose health may be

683 impacted. To break down barriers to patient engagement, the application provides a
684 novel approach to understandably communicate PGx results to laypeople. The
685 reception of this information by users will be reported in an upcoming publication.
686 Future steps include the evaluation of the costs and effectiveness of the pre-emptive
687 PGx passport in the general population and further research into the interplay
688 between genetic variation and population health and drug response phenotypes.

References

1. Abdullah-Koolmees H, Keulen AM, Nijenhuis M, Deneer VHM. Pharmacogenetics Guidelines: Overview and Comparison of the DPWG, CPIC, CPNDS, and RNPGx Guidelines. Front Pharmacol. 2021 Jan 25;11:595219.

2. Lanting P, Drenth E, Boven L, Hoek A, Hijlkema A, Poot E, et al. Practical Barriers and Facilitators Experienced by Patients, Pharmacists and Physicians to the Implementation of Pharmacogenomic Screening in Dutch Outpatient Hospital Care-An Explorative Pilot Study. J Pers Med. 2020 Dec 21;10(4):293.

3. Duarte JD, Dalton R, Elchynski AL, Smith DM, Cicali EJ, Lee JC, et al. Multisite investigation of strategies for the clinical implementation of pre-emptive pharmacogenetic testing. Genet Med. 2021 Dec;23(12):2335–41.

4. Swen JJ, Wouden CH van der, Manson LE, Abdullah-Koolmees H, Blagec K, Blagus T, et al. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study. The Lancet. 2023 Feb 4;401(10374):347–56.

5. Skokou M, Karamperis K, Koufaki MI, Tsermpini EE, Pandi MT, Siamoglou S, et al. Clinical implementation of preemptive pharmacogenomics in psychiatry. eBioMedicine [Internet]. 2024 Mar 1 [cited 2024 Aug 27];101. Available from: https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(24)00044-6/fulltext

6. Mason-Suares H, Kim W, Grimmett L, Williams ES, Horner VL, Kunig D, et al. Density matters: comparison of array platforms for detection of copy-number

711 variation and copy-neutral abnormalities. Genetics in Medicine. 2013 Sep
712 1;15(9):706–12.

713 7. Momtaz R, Ghanem N m., El-Makky N m., Ismail M a. Integrated analysis of
714 SNP, CNV and gene expression data in genetic association studies. Clinical
715 Genetics. 2018;93(3):557–66.

716 8. Taylor C, Crosby I, Yip V, Maguire P, Pirmohamed M, Turner RM. A Review of
717 the Important Role of CYP2D6 in Pharmacogenomics. Genes. 2020
718 Nov;11(11):1295.

719 9. Leitsalu L, Haller T, Esko T, Tammesoo ML, Alavere H, Snieder H, et al. Cohort
720 Profile: Estonian Biobank of the Estonian Genome Center, University of Tartu.
721 International Journal of Epidemiology. 2015 Aug 1;44(4):1137–47.

722 10. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK Biobank:
723 An Open Access Resource for Identifying the Causes of a Wide Range of
724 Complex Diseases of Middle and Old Age. PLOS Medicine. 2015
725 mrt;12(3):e1001779.

726 11. Littlejohns TJ, Sudlow C, Allen NE, Collins R. UK Biobank: opportunities for
727 cardiovascular research. European Heart Journal. 2019 Apr 7;40(14):1158–66.

728 12. Minegishi N, Nishijima I, Nobukuni T, Kudo H, Ishida N, Terakawa T, et al.
729 Biobank Establishment and Sample Management in the Tohoku Medical
730 Megabank Project. The Tohoku Journal of Experimental Medicine.
731 2019;248(1):45–55.

732 13. Mahajan S, Lu Y, Spatz ES, Nasir K, Krumholz HM. Trends and Predictors of
733 Use of Digital Health Technology in the United States. Am J Med. 2021
734 Jan;134(1):129–34.

735 14. Shen N, Jankowicz D, Strudwick G. Patient and Family Engagement Approaches
736 for Digital Health Initiatives: Protocol for a Case Study. JMIR Research Protocols.
737 2021 Jul 21;10(7):e24274.

738 15. Integraal Zorg Akkoord. 2022 Sep;

739 16. Sijtsma A, Rienks J, Harst P, Navis G, Rosmalen JGM, Dotinga A. Cohort Profile
740 Update: Lifelines, a three-generation cohort study and biobank. Int J Epidemiol.
741 2022 Oct 13;51(5):e295–302.

742 17. Scholtens S, Smidt N, Swertz MA, Bakker SJ, Dotinga A, Vonk JM, et al. Cohort
743 Profile: LifeLines, a three-generation cohort study and biobank. International
744 Journal of Epidemiology. 2015 Aug 1;44(4):1172–80.

745 18. Warmink-Perdijk WDB, Peters LL, Tigchelaar EF, Dekens JAM, Jankipersadsing
746 SA, Zhernakova A, et al. Lifelines NEXT: a prospective birth cohort adding the
747 next generation to the three-generation Lifelines cohort study. Eur J Epidemiol.
748 2020 Feb;35(2):157–68.

749 19. Warmerdam R, Lanting P, Lifelines Cohort Study, Deelen P, Franke L. Idéfix:
750 identifying accidental sample mix-ups in biobanks using polygenic scores.
751 Bioinformatics. 2022 Feb 15;38(4):1059–66.

752 20. Shah TS, Liu JZ, Floyd JAB, Morris JA, Wirth N, Barrett JC, et al. optiCall: a
753 robust genotype-calling algorithm for rare, low-frequency and common variants.
754 Bioinformatics. 2012 Jun 15;28(12):1598–603.

755 21. Franke L, el Bannoudi H, Jansen DTSL, Kok K, Trynka G, Diogo D, et al.
756 Association analysis of copy numbers of FC-gamma receptor genes for
757 rheumatoid arthritis and other immune-mediated phenotypes. European Journal
758 of Human Genetics. 2016 Feb;24(2):263–70.

759 22. Pedregosa F, Varoquaux G, Gramfort A, Michel V, Thirion B, Grisel O, et al.
760 Scikit-learn: Machine Learning in Python. Journal of Machine Learning Research.
761 2011;12(85):2825–30.

762 23. Loh PR, Danecek P, Palamara PF, Fuchsberger C, A Reshef Y, K Finucane H, et
763 al. Reference-based phasing using the Haplotype Reference Consortium panel.
764 Nat Genet. 2016 Nov;48(11):1443–8.

765 24. statgen/Minimac4 [Internet]. Center for Statistical Genetics; 2024 [cited 2024 Aug
766 27]. Available from: https://github.com/statgen/Minimac4

767 25. Byrska-Bishop M, Evani US, Zhao X, Basile AO, Abel HJ, Regier AA, et al. High-
768 coverage whole-genome sequencing of the expanded 1000 Genomes Project
769 cohort including 602 trios. Cell. 2022 Sep 1;185(18):3426-3440.e19.

770 26. Pratt VM, Del Tredici AL, Hachad H, Ji Y, Kalman LV, Scott SA, et al.
771 Recommendations for Clinical CYP2C19 Genotyping Allele Selection. The
772 Journal of Molecular Diagnostics. 2018 May;20(3):269–76.

773 27. Pratt VM, Cavallari LH, Del Tredici AL, Hachad H, Ji Y, Kalman LV, et al.
774 Recommendations for Clinical Warfarin Genotyping Allele Selection. The Journal
775 of Molecular Diagnostics. 2020 Jul;22(7):847–59.

776 28. Pratt VM, Cavallari LH, Del Tredici AL, Gaedigk A, Hachad H, Ji Y, et al.
777 Recommendations for Clinical CYP2D6 Genotyping Allele Selection. The Journal
778 of Molecular Diagnostics. 2021 Sep;23(9):1047–64.

779 29. Pratt VM, Cavallari LH, Fulmer ML, Gaedigk A, Hachad H, Ji Y, et al. *CYP3A4*
780 and *CYP3A5* Genotyping Recommendations. The Journal of Molecular
781 Diagnostics. 2023 Sep 1;25(9):619–29.

782 30. Hofmeister RJ, Ribeiro DM, Rubinacci S, Delaneau O. Accurate rare variant
783 phasing of whole-genome and whole-exome sequencing data in the UK Biobank.
784 Nat Genet. 2023 Jul;55(7):1243–9.

785 31. Kennedy S. Fluent in 3 Months. 2023 [cited 2024 Aug 28]. CEFR Levels: What
786 They Are and How to Test Yourself. Available from:
787 https://www.fluentin3months.com/cefr-levels/

788 32. Krist AH, Tong ST, Aycock RA, Longo DR. Engaging patients in decision-making
789 and behavior change to promote prevention. Stud Health Technol Inform.
790 2017;240:284–302.

791 33. Merker VL, Hyde JK, Herbst A, Solch AK, Mohr DC, Gaj L, et al. Evaluating the
792 Impacts of Patient Engagement on Health Services Research Teams: Lessons
793 from the Veteran Consulting Network. J Gen Intern Med. 2022 Apr;37(Suppl
794 1):33–41.

34. Ministerie van Volksgezondheid, Welzijn en Sport. Stand van zaken inzet DNA-technologie voor zorg en preventie [Internet]. Ministerie van Algemene Zaken; 2023 [cited 2024 Aug 27]. Available from: https://www.rijksoverheid.nl/documenten/kamerstukken/2023/10/25/kamerbrief-over-stand-van-zaken-inzet-dna-technologie-voor-zorg-en-preventie

35. Allison M, Patterson J, Burton S, Patel D, Brassil KJ. Digital engagement preferences of individuals aged 65 and older with cancer. JCO. 2020 Oct 10;38(29_suppl):289–289.

36. Borghouts J, Eikey E, Mark G, De Leon C, Schueller SM, Schneider M, et al. Barriers to and Facilitators of User Engagement With Digital Mental Health Interventions: Systematic Review. J Med Internet Res. 2021 Mar 24;23(3):e24387.

Acknowledgements

The authors thank the UMCG Genomics Coordination Center, the UG Center for Information Technology and their sponsors BBMRI-NL & TarGet for storage and compute infrastructure.

They thank Maaike van der Lee and Jesse Swen from the department of Clinical Pharmacy and Toxicology of the Leiden University Medical Center for providing the validation samples with known genotypes. The authors thank Certe Groningen for their assistance in genotyping the CYP2D6 gene in a number of cases and the GIC of the KNMP for providing their drug information texts to generate layperson-friendly information.

819 Lifelines Cohort Study

820 The Lifelines Biobank initiative has been made possible by funding from the Dutch
821 Ministry of Health, Welfare and Sport, the Dutch Ministry of Economic Affairs, the
822 University Medical Center Groningen (UMCG the Netherlands), University of
823 Groningen and the Northern Provinces of the Netherlands. The generation and
824 management of GWAS genotype data for the Lifelines Cohort Study is supported by
825 the UMCG Genetics Lifelines Initiative (UGLI). The authors wish to acknowledge the
826 services of the Lifelines Cohort Study, the contributing research centers delivering
827 data to Lifelines, and all the study participants.

828

829 Raul Aguirre-Gamboa (1), Patrick Deelen (1), Lude Franke (1), Jan A Kuivenhoven
830 (2), Esteban A Lopera Maya (1), Ilja M Nolte (3), Serena Sanna (1), Harold Snieder
831 (3), Morris A Swertz (1), Judith M Vonk (3), Cisca Wijmenga (1)

832

833 (1) Department of Genetics, University of Groningen, University Medical Center
834 Groningen, The Netherlands

835

836 (2) Department of Pediatrics, University of Groningen, University Medical Center
837 Groningen, The Netherlands

838

839 (3) Department of Epidemiology, University of Groningen, University Medical Center
840 Groningen, The Netherlands

841

Funding

This work was supported by SNN (Samenwerkingsverband Noord Nederland) [OPSNN0229 PCH Ecosysteem WP4.4]; by Lifelines NEXT, which has been made possible by funds from a grant from the UMCG Hereditary Metabolic Diseases Fund; by the grants awarded to A.Z. (Netherlands Organization for Scientific Research [NWO] VIDI Grant [016.178.056], a European Research Council [ERC] starting grant [ERC-715772], and Gravitation program EXPOSOME-NL (NWO grant number 024.004.017)), and the Lifelines Biobank initiative, which has been made possible by funds from FES (Fonds Economische Structuurversterking), SNN and REP (Ruimtelijk Economisch Programma).

L.F. is supported by grants from NWO [ZonMW-VIDI 917.14.374, ZonMW-VICI 09150182010019], by an ERC Starting grant [637640 ImmRisk] and through a Senior Investigator grant from the Oncode Institute. P.D. is funded by The Netherlands Organisation for Health Research and Development (ZonMw) [VENI 09150161910057].

Author contributions

PL, BW, MS, NK, JD and LF: conceptualization,

PL, RW, HB, TO, JS, MB, ELM, TOM, PD, JD and LF: methodology,

RW, HB, BC, JS, LJ and LF: software,

PL, RW, HB, TO, JS and MB: validation,

PL, RW, HB, TO, JS, MB, ELM and SJ: formal analysis,

SJ, JGA and DTe: investigation,

LLN, LLCS, PD, NK, JD and LF: resources,

PL, RW, HB, JS, ELM, SJ, BC and LJ: data curation,

PL, RW, HB, TO and JS: manuscript – original draft,

RW and JS: visualization,

BW, DTo, PD, NK, JD and LF: supervision,

PL, JS and JD: project administration,

NK, JD and LF: funding acquisition.

Data availability

Due to privacy reasons the individual-level data cannot be made publicly available but can be made available upon reasonable request. The individual-level data from Lifelines that support the findings in this publication were obtained from the Lifelines biobank under project application number ov21_0355. This request should be directed to the Lifelines Research Office through email (research@lifelines.nl) or by using the application form on their website (https://www.lifelines.nl/researcher/how-to-apply/apply-here). Access to the Lifelines NEXT Project data will be granted to all qualified researchers and will be governed by the provisions laid out in the LLNEXT Data Access Agreement: https://groningenmicrobiome.org/?page_id=2598. This access procedure is in place to ensure that the data is requested solely for research and scientific purposes, in compliance with the informed consent signed by Lifelines NEXT participants. Scripts and other software central to this manuscript is available on GitHub (https://github.com/molgenis/PGx-passport-pilot/ and https://github.com/molgenis/asterix). Other analyses of genotype data and publicly available reference data is performed using standard bioinformatics practices, for which the code is made available upon request.

Conflicts of interest

892 NdBV and DTo are members of the Dutch Pharmacogenetics Working Group

893 (DPWG). All other authors report no conflict of interest.